Citations

Showing 10 of 108162 citations.

Vaping and E-Cigarette Use in Children and Adolescents: Implications on Perioperative Care From the American Society of Anesthesiologists Committee on Pediatric Anesthesia, Society for Pediatric Anesthesia, and American Academy of Pediatrics Section on Ane
Rusy, Deborah A. , Honkanen, Anita , Landrigan‐Ossar, Mary, Chatterjee, Debnath , Schwartz, Lawrence , Lalwani, Kirk, Dollar, Jennifer, Clark, R. Lee , Diaz, Christina D. , Soriano, Sulpicio G. , Clark, Randall, Deutsch, Nina , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | March 29, 2021 | Volume: 133 | Issue: 3 | Pages: 562-568

10.1213/ane.0000000000005519 | PMID 33780391 Get It

Electronic cigarettes (e-cigarettes) or vaping use in adolescents has emerged as a public health crisis that impacts the perioperative care of this vulnerable population. E-cigarettes have become the most commonly used tobacco products among youth in the United States. Fruit and mint flavors and additives such as marijuana have enticed children and adolescents. E-cigarette, or vaping, product use–associated lung injury (EVALI) is a newly identified lung disease linked to vaping. Clinical presentation of EVALI can be varied, but most commonly includes the respiratory system, gastrointestinal (GI) tract, and constitutional symptoms. Clinical management of EVALI has consisted of vaping cessation and supportive therapy, including supplemental oxygen, noninvasive ventilation, mechanical ventilation, glucocorticoids, and empiric antibiotics, until infectious causes are eliminated, and in the most severe cases, extracorporeal membrane oxygenation (ECMO). Currently, although there is an insufficient evidence to determine the safety and the efficacy of e-cigarettes for perioperative smoking cessation, EVALI clearly places these patients at an increased risk of perioperative morbidity. Given the relatively recent introduction of e-cigarettes, the long-term impact on adolescent health is unknown. As a result, the paucity of postoperative outcomes in this potentially vulnerable population does not support evidence-based recommendations for the management of these patients. Clinicians should identify “at-risk” individuals during preanesthetic evaluations and adjust the risk stratification accordingly. Our societies encourage continued education of the public and health care providers of the risks associated with vaping and nicotine use and encourage regular preoperative screening and postoperative outcome studies of patients with regard to smoking and vaping use.
Acute Kidney Injury When Treating Periprosthetic Joint Infections After Total Knee Arthroplasties with Antibiotic-Loaded Spacers
Dagneaux, Louis , Limberg, Afton K. , Osmon, Douglas R. , Leung, Nelson , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Osmon, Douglas R , Berry, Daniel J , Leung, Nelson

Mayo Clinic

Journal of Bone and Joint Surgery | March 29, 2021 | Volume: 103 | Issue: 9 | Pages: 754-760

10.2106/jbjs.20.01825 | PMID 33780403 Get It

Background: Two-stage exchange arthroplasty with a high-dose antibiotic-loaded bone cement (ALBC) spacer and intravenous or oral antibiotics is the most common method of managing a periprosthetic joint infection (PJI) after a total knee arthroplasty (TKA). However, little is known about the contemporary incidence, the risk factors, and the outcomes of acute kidney injuries (AKIs) in this cohort. Methods: We identified 424 patients who had been treated with 455 ALBC spacers after resection of a PJI following a primary TKA from 2000 to 2017. The mean age at resection was 67 years, the mean body mass index (BMI) was 33 kg/m 2 , 47% of the patients were women, and 15% had preexisting chronic kidney disease (CKD). The spacers (87% nonarticulating) contained a mean of 8 g of vancomycin and 9 g of an aminoglycoside per construct (in situ for a mean of 11 weeks). Eighty-six spacers also had amphotericin B (mean, 412 mg). All of the patients were concomitantly treated with systemic antibiotics for a mean of 6 weeks. An AKI was defined as a creatinine level of ≥1.5 times the baseline or an increase of ≥0.3 mg/dL within any 48-hour period. The mean follow-up was 6 years (range, 2 to 17 years). Results: Fifty-four AKIs occurred in 52 (14%) of the 359 patients without preexisting CKD versus 32 AKIs in 29 (45%) of the 65 patients with CKD (odds ratio [OR], 5; p = 0.0001); none required acute dialysis. Overall, when the vancomycin concentration or aminoglycoside concentration was >3.6 g/batch of cement, the risk of AKI increased (OR, 1.9 and 1.8, respectively; p = 0.02 for both). Hypertension (β = 0.17; p = 0.002), perioperative hypovolemia (β = 0.28; p = 0.0001), and acute atrial fibrillation (β = 0.13; p = 0.009) were independent predictors for AKI in patients without preexisting CKD. At the last follow-up, 8 patients who had sustained an AKI had progressed to CKD, 4 of whom received dialysis. Conclusions: In our study, the largest series to date that we are aware of regarding this issue, AKI occurred in 14% of patients with normal renal function at baseline, and 2% developed CKD after undergoing a 2-stage exchange arthroplasty for a PJI after TKA. However, the risk of AKI was fivefold greater in those with preexisting CKD. The causes of acute renal blood flow impairment were independent predictors for AKI. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
A 19-month-old boy with decreased sleep and a distinctive electroencephalogram pattern
Baughn, Julie , Louis, Erik K. St. , St Louis, Erik K, St Louis, E K

Mayo Clinic

Journal of Clinical Sleep Medicine | March 29, 2021 | Volume: 17 | Issue: 7 | Pages: 1507-1511

10.5664/jcsm.9274 | PMID 33779540 Get It

Delayed renal transplant failure secondary to renal vein thrombosis in a patient with a permanent IVC filter
Lewis, K.L. , Wadei, Hani M. , Guru, Pramod , LEWIS, KRISTYN L, Guru, Pramod K , Wadei, Hani M , Patel, Payal Mukesh

Mayo Clinic

BMJ Case Reports | March 29, 2021 | Volume: 14 | Issue: 3 | Pages: e236619

10.1136/bcr-2020-236619 | PMID 33782061 Get It

Renal vein thrombosis is a rare, but potentially serious complication in patients with renal transplantation as it can lead to non-reversible graft injury and failure. Often this clinical entity is found in the early transplantation period, and the available management strategies are associated with favourable patient outcomes. The incidence, pathophysiology and outcomes for the delayed occurrence of renal vein thrombosis are unknown. The case here describes a unique situation with an excellent clinical outcome related to early diagnosis and appropriate care.
A method for quantitative evaluations of scanning‐proton dose distributions
Allred, Bryce C., Shan, Jie , Robertson, Daniel , DeWees, T.A. , Shen, Jiajian , Stoker, Joshua B., Robertson, Daniel G, DeWees, Todd A , Shen, Jiajian , Shan, Jie, Liu, Wei

Mayo Clinic

Journal of Applied Clinical Medical Physics | March 29, 2021 | Volume: 22 | Issue: 4 | Pages: 193-201

10.1002/acm2.13226 | PMID 33780142 Get It

AbstractPurposePatient‐Specific Quality Assurance (PSQA) measurement analysis depends on generating metrics representative of calculation and measurement agreement. Considering the heightened capability of discrete spot scanning protons to modulate individual dose voxels, a dose plane comparison approach that maintained all of the capabilities of the well‐established γ test, but that also provided a more intuitive error parameterization, was desired.MethodsAnalysis was performed for 300 dose planes compared by searching all calculated points within a fixed radius around each measured pixel to determine the dose deviation. Dose plane agreement is reported as the dose difference minimum (DDM) within an empirically established search radius: ΔDmin(r). This per‐pixel metric is aggregated into a histogram binned by dose deviation. Search‐radius criteria were based on a weighted‐beamlet 3σ spatial deviation from imaging isocenter. Equipment setup error was mitigated during analysis using tracked image registration, ensuring beamlet deviations to be the dominant source of spatial error. The percentage of comparison points with <3% dose difference determined pass rate.ResultsThe mean beamlet radial deviation was 0.38mm from x‐ray isocenter, with a standard deviation of 0.19mm, such that 99.9% of relevant pencil beams were within 1 mm of nominal. The dose‐plane comparison data showed no change in passing rate between a 3%/1mm ΔDmin(r) analysis (97.6 +/‐ 3.6%) and a 3%/2mm γ test (97.7 +/‐ 3.2%).ConclusionsPSQA dose‐comparison agreements corresponding to a search radius outside of machine performance limits are likely false positives. However, the elliptical shape of the γ test is too dose‐restrictive with a spatial‐error threshold set at 1 mm. This work introduces a cylindrical search shape, proposed herein as more relevant to plan quality, as part of the new DDM planar‐dose comparison algorithm. DDM accepts all pixels within a given dose threshold inside the search radius, and carries forward plan‐quality metrics in a straightforward manner for evaluation.
Comparison of the investigational device exemption and post‐approval trials of the Melody transcatheter pulmonary valve
Kreutzer, Jacqueline , Armstrong, Aimee K. , Rome, Jonathan J. , Zellers, Thomas M. , Balzer, David T. , Zampi, Jeffrey D. , Javois, Alexander J., Turner, Daniel R. , Gray, Robert G. , Moore, John W. , Weng, Shicheng, Jones, Thomas K. , Khan, Danyal , Vincent, Julie A., Hellenbrand, William E. , Bergersen, Lisa , McElhinney, Doff B. , Cabalka, Allison K. , Gray, Robert G , Moore, John W , Jones, Thomas K , McElhinney, Doff B , Cheatham, John P.

Mayo Clinic

Catheterization and Cardiovascular Interventions | March 29, 2021 | Volume: 98 | Issue: 2 | Pages: No page available

10.1002/ccd.29657 | PMID 33780150 Get It

AbstractObjectiveWe compared 5‐year outcomes of transcatheter pulmonary valve (TPV) replacement with the Melody TPV in the post‐approval study (PAS) and the investigational device exemption (IDE) trial.BackgroundAs a condition of approval of the Melody TPV after the IDE trial, the Food and Drug Administration required that a PAS be conducted to evaluate outcomes of TPV replacement in a “real‐world” environment. The 5‐year outcomes of the PAS have not been published, and the IDE and PAS trials have not been compared.MethodsThe cohorts comprised all patients catheterized and implanted at 5 IDE sites and 10 PAS sites. Differences in trial protocols were detailed. Time‐related outcomes and valve‐related adverse events were compared between the two trials with Kaplan–Meier curves and log‐rank testing.Results167 patients (median age, 19 years) were catheterized and 150 underwent TPV replacement in the IDE trial; 121 were catheterized (median age, 17 years) and 100 implanted in the PAS. Freedom from hemodynamic dysfunction (p = .61) or any reintervention (p = .74) over time did not differ between trials. Freedom from stent fracture (p = .003) and transcatheter reintervention (p = .010) were longer in PAS, whereas freedom from explant (p = .020) and TPV endocarditis (p = .007) were shorter. Clinically important adverse events (AEs) were reported in 14% of PAS and 7.2% of IDE patients (p = .056); the incidence of any particular event was low in both.ConclusionsHemodynamic and time‐related outcomes in the PAS and IDE trials were generally similar, confirming the effectiveness of the Melody TPV with real‐world providers. There were few significant complications and limited power to identify important differences in AEs. The lack of major differences in outcomes between the two studies questions the usefulness of mandated costly post‐approval studies as part of the regulatory process for Class III medical devices.
Determination of posterolateral oropharyngeal wall thickness and the potential implications for transoral surgical margins in tonsil cancer
Tomblinson, Courtney M. , Fletcher, Geoffrey P. , Hu, Leland , Mi, Lanyu , Howard, Brittany E. , Nagel, Thomas H. , Hinni, Michael L., Hoxworth, Joseph M. , Hoxworth, Joseph M

Mayo Clinic

Head & Neck | March 29, 2021 | Volume: 43 | Issue: 7 | Pages: 2185-2192

10.1002/hed.26693 | PMID 33780072 Get It

AbstractBackgroundMargins in transoral surgery for tonsil cancer can be limited by oropharyngeal wall thickness (OWT), but the normal range is not well established.MethodsIn 240 noncancer subjects, OWT was measured bilaterally in the vicinity of the tonsils with MRI. Statistical analysis was performed to assess for interaction of age, sex, location, and obesity.ResultsMean(SD) OWT measured 3.4(0.6) mm posteriorly, 3.7(2.0) mm between the styloglossus and stylopharyngeus, and 5.3(0.8) mm laterally. OWT was greater in men, correlated with obesity, decreased posteriorly and laterally in the 60–80 versus 40–59 year age groups, and increased when styloglossus/stylopharyngeus were closer. OWT was <5 mm in 36.7%–97.9% of locations, with the largest percentage below this threshold located posteriorly.ConclusionsOWT is frequently <5 mm, particularly in the posterior and intermuscular areas, suggesting that a smaller surgical margin may need to be accepted in transoral tonsil cancer surgery for anatomic reasons.
Recurrent ganglioneuroma in PTPN11‐associated Noonan syndrome: A case report and literature review
Morales‐Rosado, Joel A. , Singh, Herchran, Olson, Rory J. , Larsen, Brandon T. , Hager, Megan M., Klee, Eric W. , Dhamija, Radhika , Morales-Rosado, Joel A , Dhamija, Radhika

Mayo Clinic

American Journal of Medical Genetics Part A | March 29, 2021 | Volume: 185 | Issue: 6 | Pages: 1883-1887

10.1002/ajmg.a.62178 | PMID 33779033 Get It

AbstractNoonan syndrome (NS) is an autosomal dominant condition with variable expressivity most commonly due to a germline pathogenic variant in PTPN11, which encodes the protein tyrosine phosphatase SHP‐2. Gain‐of‐function variants in PTPN11 are known to promote oncogenic behavior in affected tissues. We report the clinical description of a young adult male presenting with relapsing ganglioneuromas, dysmorphic features, cardiac abnormalities, and multiple lentigines, strongly suspicious for NS. Solid tumor testing identified the recurrent pathogenic c.922G>A (p.Asn308Asp) in PTPN11. Proband and parental blood sampling testing confirmed c.922G>A as a de novo germline alteration. Comprehensive literature review of solid tumors specifically associated to PTPN11, indicates that this is the first documentation of ganglioneuroma and its clinical recurrence after resection in conjunction with a genetically confirmed NS diagnosis. The findings in our patient further extend the list of neuroblastic and neural crest‐derived neoplasms associated with this condition.
Impact of abuse on migraine‐related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research
Trivedi, Meesha , Dumkrieger, Gina , Chong, Catherine D. , Dodick, David W. , Schwedt, Todd J. , Dodick, David W , Schwedt, Todd J , Dumkrieger, Gina , Chong, Catherine D

Mayo Clinic

Headache: The Journal of Head and Face Pain | March 29, 2021 | Volume: 61 | Issue: 5 | Pages: 740-754

10.1111/head.14100 | PMID 33779989 Get It

Abstract Background and Objectives Prior studies have established an association between a history of abuse and the development of migraine. This cross‐sectional observational study explored the relationship between self‐reported abuse history with migraine‐related sensory hypersensitivity symptoms. Methods In total, 588 adult patients with migraine from the American Registry for Migraine Research completed questionnaires: Generalized Anxiety Disorder‐7, Patient Health Questionnaire‐2 for depression, Photosensitivity Assessment Questionnaire, Hyperacusis Questionnaire, and Allodynia Symptom Checklist. Using four binary screening questions, patients were asked to self‐report if they believed they had suffered emotional, physical, or sexual abuse in their lifetime. Differences in questionnaire scores between groups with and without a history of abuse were determined. Regression models adjusted for age, sex, and basic headache features analyzed the relationship between abuse history and sensory hypersensitivity symptoms. Moderation analysis explored the role of headache frequency in this relationship. Mediation analysis assessed the indirect (Mediated) effect (IE) of abuse on sensory hypersensitivity through depression or anxiety. Additional models analyzed relationships between sensory hypersensitivity symptoms and abuse subtypes or the number of abuse subtypes. Results Of 588 participants, 222 (38%) reported a history of abuse. Patients with a history of abuse reported statistically significantly greater average headache frequency (7.6 vs. 4.7 days, p = 0.030). Patients with a history of abuse also reported higher average or median questionnaire scores: anxiety (7.6 vs. 4.7, p < 0.001, d = 0.56), depression (1.7 vs. 1.3, p = 0.009, d = 0.24), photophobia (0.54 vs. 0.44, p < 0.001, d = 0.32), hyperacusis (19.6 vs. 14.9, p < 0.001, d = 0.49), ictal allodynia (6.0 vs. 3.0, p < 0.001, d = 0.46), and interictal allodynia (1.0 vs. 0.0, p < 0.001, d = 0.30). After controlling for patient age, sex and years lived with headache, abuse maintained a significant association with every sensory hypersensitivity measure. Headache frequency significantly moderated the relationship between a history of abuse with increased ictal allodynia ( p = 0.036). Anxiety significantly mediated the relationships between abuse with photophobia (IE = 0.03, 95% CI = 0.01–0.04), hyperacusis (IE = 1.51, 95% CI = 0.91–2.24), ictal allodynia (IE = 0.02, 95% CI = 0.01–0.04), and interictal allodynia (IE = 0.02, 95% CI = 0.01–0.06). Depression significantly mediated the relationship between abuse with photophobia (IE = 0.02, 95% CI = 0.01–0.03) and with hyperacusis (IE = 0.45, 95% CI = 0.11–0.88). The association between the individual subtypes of abuse and the number of subtypes of abuse with sensory hypersensitivity symptoms varied. Conclusion A history of abuse is associated with greater migraine‐related sensory hypersensitivity symptoms. To reduce the impact of abuse on migraine symptoms, future studies should explore mechanistic connections between abuse and migraine‐associated symptoms.
Efficacy and safety of blepharoptosis repair after incisional glaucoma surgery
Song, Allisa J. , Khanna, Cheryl L. , Jamali, Sepideh, Roddy, Gavin W. , Wagner, Lilly H.

Mayo Clinic

European Journal of Ophthalmology | March 29, 2021 | Volume: 32 | Issue: 1 | Pages: 122-128

10.1177/11206721211006643 | PMID 33779340 Get It

Purpose: There is an increased risk for development of blepharoptosis after incisional glaucoma surgery. Data on safety and efficacy of ptosis repair in this group of patients in limited. The goal of this study is to evaluate outcomes and identify potential risk factors for failure of ptosis repair in eyes with history of incisional glaucoma surgery. Methods: A retrospective chart review was performed of all patients who underwent incisional glaucoma surgery, specifically trabeculectomy or implantation of glaucoma drainage device (GDD), and subsequent ptosis repair at a single institution from 2009 to 2019. Ptosis surgery outcomes were compared to a control group who underwent ptosis repair after cataract surgery. Results: Seventy-eight eyes of 64 patients were included in the glaucoma surgery group. The rate of severe ptosis (margin reflex distance 1 ⩽ 0 mm) among glaucoma surgery patients was higher compared to control (35 of 78 (44.9%) vs 23 of 82 (28.6%). Ptosis repair was successful in 59 of 78 eyes (75.6%), which was similar to control. Risk for revision surgery was increased more than five-fold in the GDD group compared to control. There were no cases of early or late bleb-related complications. Conclusions: Ptosis repair can be performed safely in patients after incisional glaucoma surgery. Müller muscle conjunctival resection and external levator advancement are equally effective. Patients with history of GDD should be advised about the potentially increased risk of need for revision surgery.